Elsevier Inc.

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Bajorin
    Bajorin
  4. Rosenberg
    Rosenberg
  5. Iyer
    Iyer
  6. Solit
    Solit
  7. Feldman
    Feldman
  8. Morris
    Morris
  9. Slovin
    Slovin
  10. Voss
    Voss

Groups

  1. Genitourinary Oncology Service (384)
  2. Solid Tumor Oncology Division (384)
  3. Department of Medicine (383)
  4. GSK Faculty (92)
  5. Surgery (68)
  6. Survivorship Research (63)
  7. Urology (54)
  8. Hematologic Malignancies, Division of (49)
  9. Human Oncology and Pathogenesis Program (49)
  10. Department of Pathology and Laboratory Medicine (46)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (245)
  2. Meeting Abstract (120)
  3. Review (7)
  4. Conference Paper (6)
  5. Book Section (3)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Genitourinary Oncology Service (384)
  2. Solid Tumor Oncology Division (384)
  3. Department of Medicine (383)
  4. GSK Faculty (92)
  5. Surgery (68)
  6. Survivorship Research (63)

More Groups

People
  1. Robert Motzer (89)
  2. Howard Scher (72)
  3. Dean Bajorin (50)
  4. Jonathan Rosenberg (39)
  5. David Solit (33)
  6. Gopakumar Iyer (33)

More People

Years
  1. 2025 (9)
  2. 2024 (31)
  3. 2023 (12)
  4. 2022 (18)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. European Journal of Cancer (96)
  2. Clinical Genitourinary Cancer (63)
  3. Urologic Oncology: Seminars and Original Investigations (49)
  4. International Journal of Radiation Oncology, Biology, Physics (47)
  5. Seminars in Oncology (41)
  6. Hematology/Oncology Clinics of North America (10)

More Publications

Results (384)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • QT/QTc studies of abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) - Analysis of 3 phase 1/2 studies
    Meeting Abstract

    Ryan, C. J.; Danila, D. C.; Tolcher, A.; Chi, K. N.; Tran, N.; Knoblauch, R.; Kheoh, T.; Haqq, C. M.; Scher, H. I.; Molina, A.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Assessment of progression-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Negrier, S.; Bushmakin, A. G.; Cappelleri, J. C.; Charbonneau, C.; Sandin, R.; Michaelson, M. D.; Figlin, R. A.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Escudier, B.; Bukowski, R.; Rini, B. I.; Hutson, T. E.; Barrios, C. H.; Lin, X.; Fly, K.; Matczak, E.; Gore, M. E.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - Results from the COU-AA-301 phase 3 study
    Meeting Abstract

    Harland, S.; de Bono, J. S.; Haqq, C. M.; Staffurth, J. N.; Hao, Y.; Gagnon, D.; Liu, C.; Sternberg, C. N.; Molina, A.; Scher, H. I.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel
    Meeting Abstract

    Fizazi, K.; Scher, H. I.; Molina, A.; Logothetis, C. J.; Jones, R. J.; Staffurth, J. N.; Li, J.; Kheoh, T.; Haqq, C. M.; de Bono, J. S.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial)
    Meeting Abstract

    Escudier, B.; Loomis, A. K.; Kaprin, A.; Motzer, R.; Tomczak, P.; Tarazi, J.; Kim, S.; Gao, F.; Williams, J. A.; Rini, B.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Donskov, F.; Carus, A.; Barrios, C. H.; Escudier, B.; Li, S.; Perkins, J.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma
    Meeting Abstract

    Davis, M. P.; Figlin, R. A.; Hutson, T. E.; Goldstein, D.; Li, S.; Perkins, J.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Comparison of health-related quality of life (HRQoL) in patients reporting the same adverse event (AE) fatigue on different treatments
    Meeting Abstract

    Cella, D.; Bushmakin, A. G.; Cappelleri, J. C.; Charbonneau, C.; Sandin, R.; Negriers, S.; Figlin, R. A.; Michaelson, M. D.; Davis, M. P.; Motzer, R. J.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save
  • Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXis trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Cella, D.; Escudier, B.; Rini, B.; Chen, C.; Bhattacharyya, H.; Tarazi, J.; Rosbrook, B.; Kim, S.; Motzer, R.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save